Elizabeth Holmes & Theranos: The Turtleneck, the Voice, and the $9 Billion Lie

What Is the Theranos Story, and Why Revisit It Now?

Theranos promised something that sounded like a small miracle: a few drops of blood from a fingertip, and a full panel of lab results back. At its peak, investors valued the company at roughly nine billion dollars, and its founder, Elizabeth Holmes, was one of the most celebrated young entrepreneurs in the country. Then the technology failed to match the pitch, reporters and regulators started asking questions, and the company fell apart. In January 2022, a jury convicted Holmes of defrauding investors. She was later sentenced to 135 months in federal prison.

This episode starts from that record and then asks a different question than the one the jury had to answer. Not did she do it, but what kind of identity gets built around a story like this, and what happens to a person when the story stops being true? I'm also telling it now because Nathan Fielder and Lance Oppenheim's documentary You Can See Everything, which follows Holmes herself, opens October 16. I think it helps to know the record before you hear her version.

One note up front: we're not going to diagnose Elizabeth Holmes. We don't have the information to do that responsibly, and a podcast isn't the place for it. What we can do is look at patterns in her story and ask what psychological research might help us understand about them.

Who Is Elizabeth Holmes?

Elizabeth Anne Holmes was born in Washington, D.C., in 1984, into a family with deep ties to government work. By most accounts she was driven early. She studied Mandarin as a child, took college-level language classes while still in high school, and as a teenager started a small business selling translation software to Chinese universities. (There's also a well-worn story that she told a relative she wanted to be a billionaire when she was nine or ten. It's almost too perfect to lean on, and plenty of kids say grandiose things, so I wouldn't build much on it.)

She enrolled at Stanford in 2002 to study chemical engineering. A summer at the Genome Institute of Singapore, working on testing related to the SARS outbreak, pushed her toward microfluidics, the science of handling very small amounts of fluid, and toward her first big idea. It wasn't the finger-prick machine Theranos became known for. It was a wearable patch that would monitor a patient's blood, deliver medication, and adjust the dose on its own.

According to Vanity Fair's reporting, her Stanford professor Phyllis Gardner told her the biology simply didn't work that way. Holmes found a far more receptive audience in Channing Robertson, a chemical engineering professor who became the company's first board member and lent a nineteen-year-old founder a great deal of credibility. In March 2004 she left Stanford, used money her parents had set aside for her education, and started the company. It was first called Real-Time Cures, then renamed Theranos, a blend of “therapy” and “diagnosis.”

What Did Theranos Promise?

The pitch was simple, and that was its power. Instead of a needle in your arm and several vials of blood, Theranos said it could take a small finger prick, collect a few drops, and run a large menu of tests on its own machines. Results would be faster and cheaper, and eventually you'd get tested somewhere as convenient as a pharmacy.

Holmes made it personal, too. In a 2014 Fortune profile she described how deeply the idea of a needle in her arm had always disturbed her, and she framed Theranos as a way to remove one of the biggest barriers to people getting tested at all. Catch problems earlier, she argued, before people lose time they can't get back.

It's easy to hear “Theranos” today and think scam. But the problem underneath was real. Blood testing is central to modern medicine, and making it cheaper, easier, and less intimidating could genuinely help people. The dream wasn't absurd. The open question was whether anyone could build the technology to deliver it.

From early on, people with real scientific expertise warned that at least some of what she wanted to do would be extraordinarily difficult. Holmes didn't abandon the idea; she kept going. At that stage persistence looks like exactly what we admire in founders, and new technologies do exist because somebody refused to accept what others called impossible. What matters for the rest of the story is Holmes's relationship with persistence, and whether it ever left room for the word “no.”

How Did Holmes Build So Much Credibility So Fast?

For most of its early years, Theranos operated with unusual secrecy. The technology was treated as proprietary, so investors and partners were backing a grand vision they couldn't examine very closely. The money came in anyway.

Ramesh “Sunny” Balwani joined in 2009 and eventually became president and chief operating officer. The two were also in a private romantic relationship, which later came out at trial. Around them, Holmes assembled a board that read like a who's who of Washington: former Secretary of State George Shultz, Henry Kissinger, former Defense Secretary William Perry, former senator Sam Nunn, retired Marine general James Mattis, former Wells Fargo CEO Richard Kovacevich, and former senator and physician Bill Frist. It was an extraordinary collection of accomplished people, with one glaring gap: nobody with deep experience in laboratory medicine.

Still, that board did what it was meant to do. When a young founder makes huge claims, it's hard not to be reassured by the caliber of the people sitting beside her. Partnerships followed. Safeway spent about $350 million building clinics in more than 800 of its stores for Theranos testing, though the testing never launched. In 2013, Walgreens announced Theranos Wellness Centers inside some of its pharmacies.

Then the press found her. Fortune put Holmes on its cover in June 2014 and reported that Theranos had raised more than $400 million and was valued at roughly nine billion dollars, with Holmes owning a majority stake. On paper, that made her one of the youngest self-made female billionaires in the world. Magazine covers, conference stages, and lists of influential young leaders followed. By then the company and its founder were almost inseparable in the public mind: Theranos looked innovative because Holmes looked like a visionary, and she looked serious because powerful people were backing her.

How Did Holmes Construct Her Public Persona?

Alongside the company, there was the character. Holmes admired Steve Jobs openly, and the resemblance went well beyond business philosophy. She adopted his black turtleneck as a daily uniform, and Fortune's profile commented on the similarity and described Jobs as a hero of hers. Ana Arriola, a former Apple designer Holmes recruited, later said Holmes wanted the Theranos device to have an iPhone-style screen and a casing that echoed the original Macintosh. Reporting on Holmes has also described a deliberately low, slow, controlled speaking voice that became part of how she came across in meetings and interviews.

None of that is sinister on its face. Founders think about branding, young entrepreneurs imitate people they admire, and psychologists treat impression management, adjusting how we present ourselves because we care how others see us, as an ordinary part of social life. You probably don't talk to your boss exactly the way you talk to your best friend.

What stands out about Holmes is how deliberate the construction seems. Fortune's profile described the green juice, the all-black wardrobe, and the story that she sometimes examined drops of her own blood under a microscope. It also helped that she offered something Silicon Valley's famous founders mostly couldn't: a young woman who had dropped out of Stanford and was promising to fix a healthcare problem that touched nearly everyone. That story was far more compelling than “we built a new laboratory analyzer.”

What Was Actually Happening Inside Theranos?

To see the problem clearly, it helps to hold the promise up against what the machines could actually do. Theranos's earlier device, the Edison, could handle only a limited range of tests. A more ambitious machine, the miniLab, was supposed to combine several testing methods in one small box and eventually run the broad menu Holmes described publicly.

As the 2013 Walgreens launch approached, the miniLab wasn't ready. According to the SEC's later complaint, Theranos's proprietary analyzer performed only about twelve of the more than two hundred tests on its published patient menu. The Ninth Circuit's opinion in her appeal describes the same gap: Theranos had developed some 300 small-sample assays, but only twelve were ever run on the Edison. Many of the rest were run on commercially available analyzers, some of which Theranos had modified to handle tiny finger-stick samples.

Using commercial machines isn't suspicious in itself, because real laboratories use them every day. The problem was that it wasn't what Theranos was telling anyone. The SEC alleged that Holmes and the company never told their retail partners about the technological limits, and that during demonstrations for Walgreens executives, finger-stick samples were collected in a room with Theranos devices while some of the actual testing happened elsewhere on third-party machines. The result looked like a Theranos box doing the work when it wasn't.

Who Raised the Alarm Inside Theranos?

People inside the company knew there were problems long before the public did. One was Ian Gibbons, a Cambridge-trained biochemist who joined in 2005 as chief scientist. According to his wife, Rochelle, he grew increasingly worried that the machines weren't producing accurate results as Theranos moved toward putting its tests in Walgreens. The record isn't uniform on how he viewed the technology at different points, but by 2013 Rochelle described a scientist caught between an employer and scientific claims he didn't feel he could defend. He died by suicide in May 2013. It would be irresponsible to reduce that to a single cause, and we can't know everything he was experiencing. What we do know is that his wife described Theranos as a major source of stress for him.

Later that year, Erika Cheung, a 22-year-old Berkeley graduate, joined as a lab associate, excited about a company that seemed poised to change medicine. Part of her job was quality control: before you trust a machine with a patient sample, you run a sample whose correct answer you already know. Cheung later testified that the Edison machines frequently failed those checks, and described a practice of deleting data points as “outliers” until the numbers looked acceptable. Removing true outliers can be legitimate in data work. What she described was something else, curating the dataset so a failing system appeared to pass. When she raised concerns, including with Balwani, she said the message was that she should stop questioning and run the samples. She quit in April 2014.

Around the same time, Tyler Shultz, a young employee and the grandson of board member George Shultz, emailed Holmes a detailed critique of how Theranos validated its tests, including a concern that its statistical methods averaged away noise and made tests look more precise than they were. He says the response was hostile. He ended up in the uncomfortable position of taking on his own grandfather's most prized investment, and he couldn't get his grandfather to believe him. Lab director Adam Rosendorff raised repeated concerns about inaccurate results too, and later became an important source for the reporter who broke the story.

By this point the question was no longer whether Theranos had hit setbacks while attempting something unprecedented. Of course it had; that's how science goes. The question was what the company did with evidence that its technology wasn't performing the way it had been described.

What Happened to Patients Who Used Theranos Tests?

Once Theranos testing moved into Walgreens stores, the technology stopped being something people read about in profiles. Doctors ordered the tests, and patients got numbers back and made decisions based on them.

According to the Justice Department's account of the trial evidence, one physician who used Theranos received repeated PSA results far higher than his earlier results. A high PSA can signal prostate cancer, so that's not a number to ignore; when the test was repeated with conventional methods, the Theranos result proved wrong. In another case, a pregnant woman who had previously had multiple miscarriages received hCG results from Theranos suggesting she was miscarrying again. A second opinion using conventional testing showed a healthy pregnancy, and she went on to deliver a healthy baby.

None of this means every Theranos result was wrong. It means a company was selling testing as accurate and reliable while serious questions about accuracy were already circulating inside its own lab. Eventually Theranos voided results from its proprietary analyzer, which meant tests people had already received, discussed with doctors, and in some cases acted on were suddenly declared invalid.

How Did Theranos Unravel?

John Carreyrou, a healthcare reporter at The Wall Street Journal, had noticed how little independent scientific information existed about a company making such enormous medical claims. In early 2015 he received a tip that something was wrong, and Adam Rosendorff became one of his key early sources. Tyler Shultz and Erika Cheung became confidential sources too, and the more people he talked to, the harder it was to square Theranos's public claims with what employees described.

Theranos did not respond quietly. According to Carreyrou and others present, the company brought in attorney David Boies and others for a roughly five-hour meeting with the Journal in mid-2015, challenging former employees' credibility and threatening legal action. The pressure wasn't limited to the newspaper. Shultz was confronted by company lawyers at his grandfather's home. Cheung received a cease-and-desist letter after speaking with a Journal reporter. Rochelle Gibbons received a letter warning her against discussing her husband's death. And there was an awkward wrinkle at the top: Rupert Murdoch had reportedly invested around $100 million in Theranos, while his company owned the Journal. The Journal kept reporting anyway.

Regulators were circling too. In September 2015, an FDA inspection of Theranos's Newark operation listed observations that included inadequate procedures for handling complaints. In October 2015 the Journal reported that Theranos was running only a small fraction of its tests on its own Edison machines and using conventional lab equipment for most of the rest. Holmes pushed back, framing the criticism as the resistance every disruptor faces. But now it wasn't only journalists and former employees asking questions. In January 2016, the Centers for Medicare & Medicaid Services told Theranos that deficiencies at its California lab posed “immediate jeopardy” to patient health and safety, and by July the agency had imposed sanctions that included barring Holmes from owning or running a clinical lab for at least two years.

In June 2016, Walgreens ended the partnership and closed all forty Theranos Wellness Centers in its Arizona stores. In under two years, Holmes had gone from the youngest self-made female billionaire, running a nine-billion-dollar company, to a founder whose lab was being sanctioned and whose test results were being voided. That left a bigger question: was this an ambitious startup that failed spectacularly, or had its founder knowingly lied to the people who funded it and trusted it with their health?

What Did the Courts Decide About Elizabeth Holmes?

The first legal answer was civil. In March 2018, the SEC charged Holmes, Balwani, and Theranos with fraud, saying they had took in more than $700 million from investors through false or misleading claims. Some were strikingly specific: investors were told the military was using Theranos technology in Afghanistan and on medevac helicopters, and that the company expected more than $100 million in revenue in 2014 when it actually recorded little more than $100,000. Holmes settled without admitting or denying the allegations, paid a $500,000 penalty, gave up voting control, returned millions of shares, and accepted a ten-year bar from serving as an officer or director of a public company.

Criminal charges followed in June 2018. The government's case was that there were two related fraud schemes, one aimed at investors and another at patients who paid for testing. Holmes and Balwani were tried separately, and Holmes's trial in 2021 lasted nearly four months. She took the stand in her own defense, acknowledging mistakes and arguing that being wrong about whether Theranos would succeed isn't the same as intending to commit fraud. She also testified that Balwani had abused her during their relationship; Balwani denied the allegations. She didn't claim he dictated what she told investors, though, and the testimony was offered to explain the dynamic between them and her state of mind.

On January 3, 2022, the jury convicted Holmes of four crimes: one count of conspiracy to defraud investors and three counts of wire fraud involving individual investors. It's worth being precise here, because the simplified version of this story gets it wrong. She was not convicted of defrauding patients. The jury acquitted her of the patient-fraud conspiracy charge and three patient wire-fraud counts, and it couldn't reach a unanimous verdict on three further investor counts. Legally, Holmes went to prison for defrauding investors; the jury wasn't asked to decide that everything bad at Theranos was one big crime.

In November 2022 she was sentenced to 135 months, or eleven years and three months, followed by three years of supervised release. Balwani, convicted separately, received 155 months. The Ninth Circuit later affirmed Holmes's conviction, her sentence, and a restitution order of more than $452 million, in an opinion that was amended in December 2025. She began serving her sentence in 2023 and, as of this fall, remains in custody and continues to say she is innocent.

What Can Psychology Tell Us About a Persona Like Holmes's?

Three patterns stand out to me, and none of them requires a diagnosis. The first is grandiosity. In psychology, narcissistic grandiosity isn't a synonym for vanity: it involves an inflated sense of importance, fantasies of exceptional success, entitlement, and a need for admiration, and those traits exist on a spectrum. Recognizing them in someone is very different from diagnosing a personality disorder, and we can't tell you what was going on inside Holmes's head. But the pattern of exceptionalism is hard to miss, from the billionaire anecdote to leaving Stanford to wanting to transform healthcare rather than improve one lab process.

And reality kept reinforcing it. Important people did want to meet her, investors handed over hundreds of millions of dollars, and magazines called her a visionary. That's part of why confidence and grandiosity can look so alike while things are going well. Say you're going to change an industry and build a nine-billion-dollar company, and you're a visionary. If it collapses, the same person is suddenly described as delusional. (We dig into that word in our last episode, What Is a Delusion?.) Success changes how we read the personality that produced it.

The second pattern is impression management. As I said, it's normal, but Holmes's version was unusually deliberate: the turtleneck, the Apple-inspired design, the controlled voice. I don't think that means there was a fake Elizabeth Holmes hiding a real one. People often grow into the roles they practice. You dress for a job before you feel you belong in it, you imitate someone you admire, you act more confident than you feel, and eventually some of it becomes you. Research on self-presentation treats public identity as something we construct in interaction with other people. The more interesting question is what happens once you become dependent on the persona. By 2014 “Elizabeth Holmes” stood for something very specific, and that identity was worth money. It attracted investors, recruited employees, and opened doors.

It also made criticism easy to reinterpret. A scientist says the machine isn't ready: maybe they're too cautious. An employee says the data is bad: maybe they don't see the larger vision. A journalist says the claims don't hold up: that's just what happens to disruptors. Sometimes that's true, which is what makes it tricky; experts really can be wrong and new ideas really do get dismissed. But there has to be some point where someone persistent can hear “no” from reality. Otherwise conviction becomes unfalsifiable. If success proves you right and criticism also proves you right, nothing is left that could change your mind.

The third pattern is escalation of commitment, and it doesn't require any personality disorder at all. Research going back decades finds that people often keep investing in a failing course of action partly because abandoning it means admitting the earlier investment was wasted. The everyday versions are familiar: you've spent three years on a degree you hate, so quitting feels impossible; you've put five thousand dollars into a terrible car, so another two thousand starts to sound reasonable. Now scale that up. Holmes had left Stanford for Theranos, spent her entire adult life building it, recruited people she respected, persuaded powerful people to believe in her, and become famous because of it. Theranos had become the answer to the question of who Elizabeth Holmes was. Admitting it couldn't do what she'd said for years would mean telling investors, Walgreens, her board, her employees, the reporters who called her a genius, and then somehow herself.

None of this explains away fraud. Escalation of commitment can help us understand why someone keeps going; it doesn't make false statements true or remove responsibility for making them. And I'm wary of tidy explanations. Maybe she knew she was lying. Maybe she sincerely believed some version of Theranos could eventually become what she promised. Those possibilities aren't mutually exclusive. The jury concluded she intentionally defrauded investors. What a verdict can't answer, and I'm not sure a documentary can either, is exactly what Elizabeth Holmes believed about Elizabeth Holmes while she was doing it.

What Should We Know Before Watching You Can See Everything?

You Can See Everything, from Nathan Fielder and Lance Oppenheim, opens October 16. According to A24's description, Holmes invited a skeptical film crew to document her thirty-four days before she was sent to prison, and the project stretched across a three-year journey. So this isn't a film assembled from archival footage and court records. The crew spent time with Holmes directly, after Theranos had collapsed and while a prison sentence loomed.

That's why I wanted to tell this story now. The basic facts of the Theranos case are settled enough that the interesting uncertainty is no longer what happened, but how Holmes understands what happened. If you're going to watch her explain herself, it helps to know the record first:

• The promise: Theranos said a few drops of blood could replace most conventional testing.
• The technology: It didn't perform the way the company publicly claimed, and Theranos's own analyzer ran only a dozen of its tests.
• The warnings: Employees raised serious concerns, and some were threatened for speaking up.
• The patients: Real people received results that were sometimes inaccurate and later voided.
• The collapse: Regulators intervened, Walgreens walked away, and the company folded.
• The verdict: A jury found Holmes guilty of conspiring to defraud investors and of three counts of wire fraud.

Those facts don't tell us everything about Elizabeth Holmes, and they don't tell us exactly what she believed at each point along the way. But they give us something solid to compare against whatever version she tells now. The black turtleneck was a choice. The voice was a choice. The public image of a singular, world-changing founder was built over years, and that version of her is gone. I don't know that a documentary can tell us who the “real” Elizabeth Holmes is, or that there's a simple answer. After everything that happened, she's still telling her story and still asking people to understand her on her own terms. This time, at least, we'll know the history before we listen.

When someone has spent years shaping how others see them, what would convince you that you were finally seeing the person and not the performance?